Zydus Lifesciences revenue and financials
₹1,153.00Change from previous close: −0.56%Absolute change: −₹6.50
In the fiscal year ended March 2026, Zydus Lifesciences reported revenue of ₹267.2B (+18.37% year over year). Net income was ₹50.4B, a net margin of 18.9%.
Fiscal year ending in March. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +18.37%
- FY to Mar 2026 vs FY to Mar 2025
- Net income growth
- +11.37%
- FY to Mar 2026 vs FY to Mar 2025
- Net margin
- 18.9%
- FY to Mar 2025: 20.0%
Financial data
Amounts in millions of INR; per-share values in INR; shares in millions.
| Item | FY to Mar 2026 | FY to Mar 2025 | FY to Mar 2024 | FY to Mar 2023 | FY to Mar 2022 |
|---|---|---|---|---|---|
| Total assets | 524,066 | 372,017 | 292,808 | 257,564 | — |
| Current assets | 199,061 | 170,461 | 115,014 | 100,164 | — |
| Cash and equivalents | 8,552 | 8,268 | 4,130 | 4,878 | — |
| Short-term investments | 41,159 | 48,148 | 9,667 | 7,188 | — |
| Inventory | 56,281 | 39,440 | 34,419 | 34,133 | — |
| Net property, plant and equipment | 107,297 | 75,597 | 70,492 | 69,731 | — |
| Goodwill | 75,427 | 52,421 | 52,660 | 48,044 | — |
| Other intangible assets | 98,652 | 32,236 | 26,110 | 10,905 | — |
| Long-term investments | 11,666 | 11,431 | 5,294 | 4,576 | — |
| Current liabilities | 157,119 | 90,416 | 53,419 | 55,307 | — |
| Accounts payable | 28,451 | 22,807 | 21,267 | 21,250 | — |
| Long-term debt | 31,880 | 0.0 | 0.0 | 0.0 | — |
| Total debt | 124,960 | 32,132 | 8,042 | 11,949 | — |
| Total liabilities | 228,244 | 108,433 | 71,792 | 60,681 | — |
| Total equity (incl. minority) | 295,822 | 263,584 | 221,016 | 196,883 | — |
| Retained earnings | 284,879 | 245,616 | 203,690 | 171,898 | — |
| Minority interest | 24,708 | 24,053 | 22,721 | 21,725 | — |